% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Burghaus:21473,
      author       = {Burghaus, L. and Eggers, C. and Timmermann, L. and Fink,
                      G.R.},
      title        = {{H}allucinations in neurodegenerative diseases},
      journal      = {CNS neuroscience $\&$ therapeutics},
      volume       = {18},
      issn         = {1755-5949},
      address      = {Oxford},
      publisher    = {Wiley-Blackwell},
      reportid     = {PreJuSER-21473},
      pages        = {149 - 159},
      year         = {2012},
      note         = {Record converted from VDB: 12.11.2012},
      abstract     = {Patients with neurodegenerative disease frequently
                      experience hallucinations and illusionary perceptions. As
                      early symptoms, hallucinations may even have diagnostic
                      relevance (i.e., for the diagnosis of Lewy Body Dementia).
                      In the later course of the disease, hallucinations may
                      appear as characteristic symptoms and often constitute a
                      particular challenge for therapeutic endeavors. Here, the
                      distinction of disease-inherent hallucinations from
                      medication-associated perceptual disturbances is
                      particularly relevant. Synucleinopathies and tauopathies
                      have different risk profiles for hallucinations. In
                      synucleinopathies hallucinations are much more frequent and
                      phenomenology is characterized by visual, short-lived
                      hallucinations, with insight preserved for a long time. A
                      “double hit” theory proposes that dysfunctionality of
                      both associative visual areas and changes of limbic areas or
                      the ventral striatum are required. In contrast, in
                      tauopathies the hallucinations are more rare and mostly
                      embedded in confusional states with agitation and with
                      poorly defined or rapidly changing paranoia. The occurrence
                      of hallucinations has even been proposed as an exclusion
                      criterion for tauopathies with Parkinsonian features such as
                      progressive supranuclear palsy. To date, treatment remains
                      largely empirical, except the use of clozapine and
                      cholinesterase inhibitors in synucleinopathies, which is
                      evidence-based. The risk of increased neuroleptic
                      sensitivity further restricts the treatment options in
                      patients with Lewy Body Dementia. Coping Strategies and
                      improvement of visual acuity and sleep quality may be useful
                      therapeutic complements.},
      keywords     = {Adaptation, Psychological / Animals / Hallucinations:
                      epidemiology / Hallucinations: psychology / Hallucinations:
                      therapy / Humans / Neurodegenerative Diseases: epidemiology
                      / Neurodegenerative Diseases: psychology / Neurodegenerative
                      Diseases: therapy / Parkinson Disease: epidemiology /
                      Parkinson Disease: psychology / Parkinson Disease: therapy /
                      Sleep Disorders: epidemiology / Sleep Disorders: psychology
                      / Sleep Disorders: therapy / J (WoSType)},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {Funktion und Dysfunktion des Nervensystems (FUEK409) /
                      89572 - (Dys-)function and Plasticity (POF2-89572)},
      pid          = {G:(DE-Juel1)FUEK409 / G:(DE-HGF)POF2-89572},
      shelfmark    = {Neurosciences / Pharmacology $\&$ Pharmacy},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:21592320},
      UT           = {WOS:000300001700008},
      doi          = {10.1111/j.1755-5949.2011.00247.x},
      url          = {https://juser.fz-juelich.de/record/21473},
}